title: The effect of fluoxetine on progression in progressive multiple sclerosis: a double-blind, randomized, placebo-controlled trial.
abstract: Preclinical studies suggest that fluoxetine may have neuroprotective properties. In this pilot study forty-two patients with secondary or primary progressive MS were randomized to receive fluoxetine 20 mg twice daily or placebo for 2 years. Every 3 months the Expanded Disability Status Scale (EDSS), 9-hole peg test (9-HPT) and ambulation index (AI) were assessed. Brain MRI scans, Multiple Sclerosis Functional Composite, Fatigue Impact Scale, Guy's neurological disability Scale and SF-36 were performed at baseline, year 1 and year 2. Seven out of 20 (35%) patients in the fluoxetine group and 7 out of 22 (32%) patients in the placebo group had sustained progression on the EDSS, 9-HPT, or AI at 2 years. No differences were identified between the 2 treatment groups with respect to secondary clinical outcomes and T2 lesion load, grey matter volume and white matter volume. An unanticipated low rate of disability progression in the placebo group decreased the statistical power. At least 200 patients would have been needed to detect a 50% treatment effect. This trial shows that fluoxetine was generally well tolerated, but no assumptions can be made about a possible treatment effect. An adequately powered controlled trial of fluoxetine in progressive MS is still warranted. This trial is registered with Current Controlled Trials ISRCTN38456328.
authors: Department of Neurology, University Medical Center Groningen, University of Groningen, Postbus 30.001, 9700 RB Groningen, The Netherlands ; Department of Neurology, Rijnstate Hospital, Postbus 9555, 6800 TA Arnhem, The Netherlands.
authors: Jop
authors: J
authors: Mostert
authors: Thea
authors: T
authors: Heersema
authors: Manju
authors: M
authors: Mahajan
authors: Jeroen
authors: J
authors: Van Der Grond
authors: Mark A
authors: MA
authors: Van Buchem
authors: Jacques
authors: J
authors: De Keyser
references: Brain. 1999 May;122 ( Pt 5):871-82
references: 10355672
references: Trends Pharmacol Sci. 2004 Feb;25(2):67-71
references: 15102491
references: Curr Neurol Neurosci Rep. 2009 Sep;9(5):411-7
references: 19664372
references: Neurology. 2004 Nov 23;63(10):1788-95
references: 15557491
references: J Psychosom Res. 2004 Feb;56(2):157-70
references: 15016573
references: Neuroimage. 2004;23 Suppl 1:S208-19
references: 15501092
references: Lancet Neurol. 2011 Feb;10(2):123-30
references: 21216670
references: J Neurol Neurosurg Psychiatry. 2008 Sep;79(9):1027-31
references: 18450787
references: Brain. 2005 May;128(Pt 5):1016-25
references: 15758036
references: Ann Neurol. 1995 Jan;37(1):30-40
references: 7818255
references: Brain. 2002 Jan;125(Pt 1):75-85
references: 11834594
references: Cochrane Database Syst Rev. 2009 Jan 21;(1):CD006643
references: 19160292
references: Ann Neurol. 2007 Jan;61(1):14-24
references: 17262850
references: J Physiol. 2003 Jun 1;549(Pt 2):501-12
references: 12679378
references: Neuroimage. 2010 Jan 15;49(2):1259-70
references: 19682588
references: J Neurochem. 2009 May;109 Suppl 1:80-6
references: 19393012
references: Mult Scler. 2009 Jun;15(6):715-20
references: 19383646
references: Neurosci Lett. 2006 Jul 10;402(1-2):22-4
references: 16644118
references: Drug Saf. 2004;27(14):1157-65
references: 15554748
references: Ann Neurol. 2005 Dec;58(6):840-6
references: 16283615
references: Psychopharmacology (Berl). 2011 Jul;216(1):75-84
references: 21301813
references: Neurology. 1999 Nov 10;53(8):1628-33
references: 10563603
references: Brain Res. 2010 Dec 2;1363:143-50
references: 20858471
references: Neuroimage. 2005 Nov 15;28(3):607-17
references: 16129626
references: Spine (Phila Pa 1976). 2000 Dec 15;25(24):3130-9
references: 11124729
references: Neurology. 1983 Nov;33(11):1444-52
references: 6685237
references: J Neurosci Res. 2009 Mar;87(4):1037-45
references: 18855941
references: Neurochem Res. 2002 Feb;27(1-2):113-20
references: 11930908
references: N Engl J Med. 1983 Jan 27;308(4):173-80
references: 6294517
references: J Neurol Sci. 2007 Apr 15;255(1-2):35-41
references: 17331540
references: Mult Scler. 1999 Aug;5(4):223-33
references: 10467380